Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 5,852 matching trials from the live ClinicalTrials.gov search.
Filters: "gene therapy" Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sleep Health, Inflammation, and Emotion Study

NCT02270619
View directory record Official record
Conditions
Depression
Interventions
Endotoxin, Partial sleep deprivation, Placebo, Uninterrupted sleep
Biological · Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years to 80 Years · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 17, 2026, 1:04 AM EDT
Terminated Phase 1 Interventional

Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer

NCT02592967
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
JNJ-64041757 (Cohort 1A and 1B), JNJ-64041757 (Cohort 2A and 2B)
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Duarte, California • Baltimore, Maryland • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 1 Interventional

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

NCT02323607
View directory record Official record
Conditions
Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Pacritinib, Cytarabine, Daunorubicin Hydrochloride, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Bhavana Bhatnagar
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

NCT03789175
View directory record Official record
Conditions
Cancer, Skin Fibroblasts, Muscle Weakness
Interventions
Nicotinamide Riboside (NR)
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 17, 2026, 1:04 AM EDT
Terminated Phase 2 Interventional Results available

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

NCT02658812
View directory record Official record
Conditions
Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Inflammatory Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Talimogene Laherparepvec
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

NCT03689712
View directory record Official record
Conditions
Oral Mucositis
Interventions
GC4419 90mg, Placebo
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
86
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Corona, California + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819
View directory record Official record
Conditions
Advanced Solid Tumors, HER2 Mutation
Interventions
BAY2927088
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Completed No phase listed Observational

Phenotype/Genotype Correlations in Neuromuscular Disorders

NCT00017745
View directory record Official record
Conditions
Neuromuscular Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting Phase 2 Interventional

Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis

NCT05427695
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Lactobacillus sakei proBio65, Isotonic Saline Solution
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)

NCT02339012
View directory record Official record
Conditions
Healthy Volunteers, Non-Healthy/Non-Frail, Frail
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
20 Years to 120 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2099
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

NCT01420081
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
PF-05212384
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 17, 2026, 1:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area

NCT00913757
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Alcoholic, Hepatitis, Chronic, Hepatitis, Viral, Human
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
1,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

NCT06161519
View directory record Official record
Conditions
Glioma, Medulloblastoma, Ependymoma, Glioblastoma
Interventions
PLX038
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

NCT04129216
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen Citrate, Letrozole, Exemestane, Blueprint, Mammaprint
Drug · Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy

NCT03493607
View directory record Official record
Conditions
Phelan-McDermid Syndrome, Epilepsy
Interventions
AMO-01
Drug
Lead sponsor
Alexander Kolevzon
Other
Eligibility
12 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting Not applicable Interventional

Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention

NCT06055036
View directory record Official record
Conditions
Cardiometabolic Syndrome, Physical Inactivity, Hypertension, Type 2 Diabetes, PreDiabetes, Obesity, Cardiovascular Diseases, Smoking, Sleep, Hyperlipidemias, Diet, Healthy, Blood Pressure
Interventions
Black Impact Intervention
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Male only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

NCT03406611
View directory record Official record
Conditions
Homocystinuria
Interventions
Pegtibatinase, Placebo
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Regulation of Mucosal Healing in Inflammatory Bowel Disease

NCT04504136
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Serial Biopsy
Procedure
Lead sponsor
Terrence A Barrett
Other
Eligibility
18 Years to 90 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment

NCT06800092
View directory record Official record
Conditions
Cancer
Interventions
Sildenafil
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting Phase 2 Interventional

Transcutaneous Vagus Nerve Stimulation in SLE

NCT06987565
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Active vagus nerve stimulation, Sham vagus nerve stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting Phase 1 Interventional

Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders

NCT07585136
View directory record Official record
Conditions
Bone Marrow Failure Syndrome
Interventions
Filgrastim, Plerixafor, Leukapheresis
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting No phase listed Observational

Novel Genetic Disorders of the Immune System

NCT02257892
View directory record Official record
Conditions
PI3KCD, CTLA4, STAT3GOF, MAGT1
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 1 Interventional

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

NCT03215511
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Selitrectinib (BAY2731954)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Month and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Not applicable Interventional Results available

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

NCT01293032
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy
Procedure · Other · Genetic + 1 more
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 17, 2026, 1:04 AM EDT